Weifeng Tang

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 10

Top Topics

Rheumatoid Arthritis Patients

Disease Activity

Top Venues

Diabetes, obesity & metabolism

Clinical pharmacokinetics

British journal of clinical pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Weifeng Tang, Raj Tummala, Joachim Almquist, Michael Hwang, Wendy I White, David W Boulton, Alexander MacDonald
Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anifrolumab. Clinical pharmacokinetics 62 (5) (2023)
Weifeng Tang, Raj Tummala, Joachim Almquist, Michael Hwang, Wendy I White, David W Boulton, Alexander MacDonald
Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anifrolumab. Clinical pharmacokinetics 62 (5) (2023)
Johanna Melin, Joanna Parkinson, Bengt Hamrén, Robert C Penland, David W Boulton, Weifeng Tang
Dapagliflozin pharmacokinetics is similar between patients with heart failure with reduced ejection fraction and patients with type 2 diabetes mellitus. British journal of clinical pharmacology (2023)
Weifeng Tang, Raj Tummala, Joachim Almquist, Michael Hwang, Wendy I White, David W Boulton, Alexander MacDonald
Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anifrolumab. Clinical pharmacokinetics (2023)
Weifeng Tang, Raj Tummala, Joachim Almquist, Michael Hwang, Wendy I White, David W Boulton, Alexander MacDonald
Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anifrolumab. Clinical pharmacokinetics 62 (5) (2023)
Millie Shah, Leonid A Stolbov, Tatiana Yakovleva, Weifeng Tang, Victor Sokolov, Robert C Penland, David W Boulton, Joanna Parkinson
A model-based approach to investigating the relationship between glucose-insulin dynamics and dapagliflozin treatment effect in patients with type 2 diabetes. Diabetes, obesity & metabolism 23 (4) (2021)
Joanna Parkinson, Weifeng Tang, Magnus Åstrand, Johanna Melin, Ella Ekholm, Bengt Hamrén, David W Boulton
Model-based characterization of the relationship between dapagliflozin systemic exposure and HbA1c response in patients with type 1 diabetes mellitus. Diabetes, obesity & metabolism 21 (6) (2019)
Tatiana Yakovleva, Victor Sokolov, Lulu Chu, Weifeng Tang, Peter J Greasley, Helena Peilot Sjögren, Susanne Johansson, Kirill Peskov, Gabriel Helmlinger, David W Boulton, Robert C Penland
Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors. Diabetes, obesity & metabolism 21 (12) (2019)
Victor Sokolov, Tatiana Yakovleva, Shinya Ueda, Joanna Parkinson, David W Boulton, Robert C Penland, Weifeng Tang
Urinary glucose excretion after dapagliflozin treatment: An exposure-response modelling comparison between Japanese and non-Japanese patients diagnosed with type 1 diabetes mellitus. Diabetes, obesity & metabolism 21 (4) (2018)
Hirotaka Watada, Masanari Shiramoto, Shinya Ueda, Weifeng Tang, Michiko Asano, Fredrik Thorén, Hyosung Kim, Toshitaka Yajima, David W Boulton, Eiichi Araki
Pharmacokinetics and pharmacodynamics of dapagliflozin in combination with insulin in Japanese patients with type 1 diabetes. Diabetes, obesity & metabolism 21 (4) (2018)